Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 July 2023 | Story Leonie Bolleurs | Photo Stephen Collett
Prof Oliver Mutanga and Prof Melanie Walker
Prof Oliver Mutanga, one of the first PhD gradautes under the SARChI Chair in Higher Education and Human Development, pictured with his former supervisor, Prof Melanie Walker, during his first visit to the university after ten years.

Prof Oliver Mutanga, a University of the Free State (UFS) alumnus with a PhD in Development Studies and an experienced researcher focused on matters pertaining to disability, education, equality, and health issues, recently took up the position of Assistant Professor in the Graduate School of Education at the Nazarbayev University in Astana, Kazakhstan.

Prof Melanie Walker, Director of the SARChI Chair in Higher Education and HumanDevelopment (HEHD) at the UFS, invited Prof Mutanga to discuss his own research via an open webinar and to engage with members of her research group.

Prof Walker explained that she was delighted to host Dr Mutanga at the university, given his profile as an outstanding and internationally mobile early career researcher, from whom others in her group could learn. “Further, I very much wanted Dr Mutanga to speak about his own research, given its overall academic excellence, quality, and impact. Going forward, I am looking forward to developing this link with Dr Mutanga and his colleagues abroad around critical diversity studies,” she states.

Profs Walker and Mutanga have collaborated in the past to write articles for academic journals arising from his doctoral research. Examples include, ‘Towards a disability-inclusive higher education policy through the capabilities approach’ (published in the Journal of Human Development and Capabilities) as well as ‘Exploration of the academic lives of students with disabilities at South African universities: Lecturers’ perspectives’ (published in the African Journal of Disability).

Prior to joining Nazarbayev University, Prof Mutanga gained valuable research and development experience in various countries, including Zimbabwe, Botswana, South Africa, Norway, and the United Kingdom.

He has also received several accolades for his work, including the prestigious Marie Sklodowska Curie Postdoctoral Fellowship at the University of Oslo, Norway, and the Global Challenges Research Fellowship at University College London's Institute of Education.

A unique outlook on disability

In 2013, Prof Mutanga was part of the first cohort of PhD students under the SARChI Chair in Higher Education and Human Development. Recently, during his three-day visit to the UFS, he addressed the HEHD research group and an international academic audience during a hybrid seminar on the perceptions and experiences of disability within the Tembo Mvura communities of Northern Zimbabwe.

In his research for this paper, Prof Mutanga uses storytelling and in-depth interviews to offer a distinctive, community-based, and Southern interpretation of disability. By applying the capabilities approach and the ubuntu philosophy, his study presents a contrast to Western perceptions of disability that often emphasise individual limitations and differences based on physical and mental characteristics, which have the potential to both result in isolation and to understanding people as autonomous but isolated beings.

Within the Tembo Mvura communities, he discovered that disability is viewed through a lens of interconnectedness between individuals, their environment, and the spiritual world: “They recognise the inherent worth and dignity of all individuals, irrespective of their impairments,” found Prof Mutanga. Indeed, impairment of full personhood is understood as lacking in any of the three dimensions outlined above.

Thus, Prof Mutanga explored the complex interaction of identity, access to land, laws, and language, as well as labelling, highlighting how these factors shape perceptions and experiences of disability within these communities.

He is of the view that these findings will have implications for North-dominated disability discourse and for policy, practice, and research within indigenous contexts, such as the Tembo Mvura, where disability is uniquely perceived and experienced.

In addition to the hybrid seminar, Prof Mutanga led valuable sessions with the HEHD Research Group, where the PhD and postdoctoral fellows had the opportunity to workshop and refine various aspects of their current research papers and to engage in discussions around building their academic careers.

News Archive

Research contributes to improving quality of life for cancer patients
2016-11-21

Description: Inorganic Chemistry supervisors  Tags: Inorganic Chemistry supervisors

Inorganic Chemistry supervisors in the Radiopharmacy
Laboratory during the preparation of a typical complex
mixture to see how fast it reacts. Here are, from the left,
front: Dr Marietjie Schutte-Smith, Dr Alice Brink
(both scholars from the UFS Prestige
Scholar Programme), and Dr Truidie Venter (all three
are Thuthuka-funded researchers).
Back: Prof André Roodt and Dr Johan Venter.
Photo: Supplied

Imagine that you have been diagnosed with bone cancer and only have six months to live. You are in a wheelchair because the pain in your legs is so immense that you can’t walk anymore – similar to a mechanism eating your bones from the inside.

You are lucky though, since you could be injected with a drug to control the pain so effective that you will be able to get out of the wheelchair within a day-and-a-half and be able to walk again. Real-life incidents like these provide intense job satisfaction to Prof André Roodt, Head of Inorganic Chemistry at the University of the Free State (UFS). The research, which is conducted by the Inorganic Group at the UFS, contributes greatly to the availability of pain therapy that does not involve drugs, but improves the quality of life for cancer patients.

The research conducted by the Inorganic Group under the leadership of Prof Roodt, plays a major role in the clever design of model medicines to better detect and treat cancer.

The Department of Chemistry is one of approximately 10 institutions worldwide that conducts research on chemical mechanisms to identify and control cancer. “The fact that we are able to cooperate with the Departments of Nuclear Medicine and Medical Physics at the UFS, the Animal Research Centre, and other collaborators in South Africa and abroad, but especially the methodology we utilise to conduct research (studying the chemical manner in which drugs are absorbed in cancer as well as the time involved), enhances the possibility of making a contribution to cancer research,” says Prof Roodt.

Technique to detect cancer spots on bone
According to the professor, there are various ways of detecting cancer in the body. Cancer can, inter alia, be identified by analysing blood, X-rays (external) or through an internal technique where the patient is injected with a radioactive isotope.

Prof Roodt explains: “The doctor suspects that the patient has bone cancer and injects the person with a drug consisting of an isotope (only emits X-rays and does no damage to tissue) that is connected to a phosphonate (similar to those used for osteoporosis). Once the drug is injected, the isotope (Technetium-99m) moves to the spot on the bone where the cancer is located. The gamma rays in the isotope illuminate the area and the doctor can see exactly where treatment should be applied. The Technetium-99m has the same intensity gamma rays as normal X-rays and therefore operates the same as an internal X-ray supply.” With this technique, the doctor can see where the cancer spots are within a few hours.

The same technique can be used to identify inactive parts of the brain in Alzheimer patients, as well as areas of the heart where there is no blood supply or where the heart muscle is dead.

Therapeutic irradiation of cancer
For the treatment of pain connected with cancer, the isotope Rhenium-186 is injected. Similar to the manner in which the Technetium-99m phosphonate compound is ingested into the body, the Rhenium-186 phosphonate travels to the cancer spots. Patients thus receive therapeutic irradiation – a technique known as palliative therapy, which is excellent for treating pain. A dosage of this therapy usually lasts for about two months.

The therapy is, however, patient specific. The dosages should correspond with the occurrence and size of cancer spots in the patient’s body. First, the location of the cancer will be determined by means of a technetium scan. After that, the size of the area where the cancer occurs has to be determined. The dosage for addressing total pain distribution will be calculated according to these results.

Technique to detect cancer spots on soft tissue
Another technique to detect cancer as spots on bone or in soft tissue and organs throughout the body is by utilising a different type of irradiation, a so-called PET isotope. The Fluor-18 isotope is currently used widely, and in Pretoria a machine called a cyclotron was produced by Dr Gerdus Kemp, who is a former PhD graduate from the Inorganic Research Group. The F-18 is then hidden within a glucose molecule and a patient will be injected with the drug after being tranquillised and after the metabolism has been lowered considerably. The glucose, which is the ‘food' that cancer needs to grow, will then travel directly to the cancer area and the specific area where the cancer is located will thus be traced and ‘illuminated’ by the Fluor-18, which emits its own 'X-rays'.

In the late 80s, Prof Roodt did his own postdoctoral study on this research in the US. He started collaborating with the Department of Nuclear Medicine at the UFS in the early 90s, when he initiated testing for this research.

Through their research of more than 15 years, the Inorganic Group in the Department of Chemistry has made a major contribution to cancer research. Research on mechanisms for the detection of cancer, by designing new clever chemical agents, and the chemical ways in which these agents are taken up in the body, especially contributes to the development in terms of cancer therapy and imaging, and has been used by a number of hospitals in South Africa.

The future holds great promise
Prof Roodt and his team are already working on a bilateral study between the UFS and Kenya. It involves the linking of radio isotopes, as mentioned above, to known natural products (such as rooibos tea), which possess anti-cancer qualities.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept